Wealthfront Advisers’s Labcorp LH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.37M | Sell |
8,474
-420
| -5% | -$110K | ﹤0.01% | 577 |
|
|
2026
Q1 | $2.37M | Buy |
8,894
+1,370
| +18% | +$371K | 0.01% | 573 |
|
|
2025
Q4 | $1.89M | Buy |
7,524
+107
| +1% | +$28.4K | ﹤0.01% | 604 |
|
|
2025
Q3 | $2.13M | Buy |
7,417
+167
| +2% | +$44.7K | 0.01% | 574 |
|
|
2025
Q2 | $1.9M | Buy |
7,250
+685
| +10% | +$167K | ﹤0.01% | 583 |
|
|
2025
Q1 | $1.53M | Buy |
6,565
+114
| +2% | +$27.7K | ﹤0.01% | 590 |
|
|
2024
Q4 | $1.48M | Buy |
6,451
+64
| +1% | +$14.7K | ﹤0.01% | 593 |
|
|
2024
Q3 | $1.43M | Sell |
6,387
-859
| -12% | -$189K | ﹤0.01% | 573 |
|
|
2024
Q2 | $1.47M | Buy |
7,246
+2,289
| +46% | +$466K | 0.01% | 549 |
|
|
2024
Q1 | $1.08M | Sell |
4,957
-614
| -11% | -$135K | ﹤0.01% | 599 |
|
|
2023
Q4 | $1.27M | Buy |
5,571
+1,057
| +23% | +$222K | ﹤0.01% | 553 |
|
|
2023
Q3 | $908K | Sell |
4,514
-1,042
| -19% | -$220K | ﹤0.01% | 578 |
|
|
2023
Q2 | $1.15M | Sell |
5,556
-2,998
| -35% | -$582K | ﹤0.01% | 529 |
|
|
2023
Q1 | $1.69M | Sell |
8,554
-3,793
| -31% | -$781K | 0.01% | 443 |
|
|
2022
Q4 | $2.5M | Sell |
12,347
-2,658
| -18% | -$519K | 0.01% | 349 |
|
|
2022
Q3 | $2.64M | Buy |
15,005
+3,375
| +29% | +$691K | 0.01% | 306 |
|
|
2022
Q2 | $2.34M | Buy |
11,630
+6,619
| +132% | +$1.41M | 0.01% | 340 |
|
|
2022
Q1 | $1.14M | Sell |
5,011
-5,102
| -50% | -$1.2M | 0.01% | 503 |
|
|
2021
Q4 | $2.73M | Buy |
10,113
+572
| +6% | +$142K | 0.01% | 324 |
|
|
2021
Q3 | $2.31M | Buy |
9,541
+6,245
| +189% | +$1.57M | 0.01% | 320 |
|
|
2021
Q2 | $781K | Buy |
3,296
+648
| +24% | +$148K | ﹤0.01% | 461 |
|
|
2021
Q1 | $580K | Buy |
2,648
+343
| +15% | +$68.8K | ﹤0.01% | 441 |
|
|
2020
Q4 | $403K | Buy |
2,305
+61
| +3% | +$10.5K | ﹤0.01% | 465 |
|
|
2020
Q3 | $363K | Buy |
2,244
+85
| +4% | +$13.5K | ﹤0.01% | 446 |
|
|
2020
Q2 | $308K | Buy |
+2,159
| New | +$299K | ﹤0.01% | 449 |
|
|
2020
Q1 | – | Sell |
-2,393
| Closed | -$348K | – | 472 |
|
|
2019
Q4 | $348K | Buy |
2,393
+2
| +0.1% | +$289 | ﹤0.01% | 437 |
|
|
2019
Q3 | $345K | Buy |
2,391
+72
| +3% | +$10.5K | ﹤0.01% | 415 |
|
|
2019
Q2 | $344K | Buy |
2,319
+223
| +11% | +$31.1K | ﹤0.01% | 422 |
|
|
2019
Q1 | $276K | Buy |
+2,096
| New | +$258K | ﹤0.01% | 433 |
|
Other funds holding LH
Wealthfront Advisers's LH Position: Q2 2026 in Review
Wealthfront Advisers reduced its Labcorp (LH) stake by 4.7% in Q2 2026, selling an estimated $110K and leaving 8,474 shares worth $2.37M. The position accounts for ﹤0.01% of the portfolio, ranked #577.
Wealthfront Advisers first reported a position in LH in Q1 2019 and has held it in 29 quarters since. The position peaked at $2.73M in Q4 2021. 1,060 funds tracked by Wall St. Rank hold LH as of Q2 2026.
- Wealthfront Advisers held 8,474 shares of Labcorp worth $2.37M as of Q2 2026.
- Wealthfront Advisers sold 420 Labcorp shares in Q2 2026, an estimated $110K.
- Labcorp made up ﹤0.01% of Wealthfront Advisers's portfolio in Q2 2026, its #577 holding.
- Wealthfront Advisers first reported a position in Labcorp in Q1 2019 and has held it in 29 quarters since.
- Wealthfront Advisers's Labcorp position peaked at $2.73M in Q4 2021.
- 1,060 funds tracked by Wall St. Rank held Labcorp as of Q2 2026.
Based on Wealthfront Advisers's 13F filing for Q2 2026, filed 7 Aug 2026.